To the thread -- Like many I sometimes think BOL could move faster on its commitment to PARS. The ff. reminds me of how busy internally BOL is during the restructuring, and also that Wall Street reads its plans optimistically. Hope we'll go for the ride too:
--------------------------------
The following is courtesy of OPTISTOCK , a weekly e-mail newsletter covering publicly-traded optical and vision care companies.
From: Editor@OPTISTOCK.COM (OptiStock)
July 26, 1998
ANALYST ACTION
Deutsche Bank upgraded Bausch & Lomb (BOL, 51-1/16) from Hold to Accumulate.
Bausch & Lomb (BOL, 51-1/16): Earnings are up 173 percent over second quarter last year, at $55.5 million, for a profit of 98 cents per diluted share, up from last year's 36 cents. Sales rose 21 percent, to $635.1 million. B&L is restructuring to cut $100 million in costs by next year and eliminate 1,900 of its 15,000+ jobs. Sales in the ophthalmic drug and surgical businesses reached $162.9 million (three times last year's figure, due to acquisitions). Sunglass sales rose only 1 percent, mostly because of lower orders from Sunglass Hut (RAYS, 9-1/32), while vision care revenues increased 4 percent. |
